Cellular Biomedicine Group Announces Key 2014 Milestone Achieved

Cellular Biomedicine Group Announces Key 2014 Milestone Achieved

Commencement of Phase IIb Clinical Trial for ReJoin(TM) Treatment of Knee
Osteoarthritis (KOA)

PALO ALTO, Calif., April 4, 2014 (GLOBE NEWSWIRE) -- Cellular Biomedicine
Group, Inc. (OTCQB:CBMG) today announced that is has begun and is enrolling
patients for its Phase IIb clinical trial for human ReJoin^TM adipose-derived
mesenchymal precursor cell (haMPC) therapy for Knee Osteoarthritis (KOA),
which tests the safety and efficacy of intra-articular injections of
autologous haMPCs in order to reduce inflammation and repair damaged joint
cartilage.

The Phase I/IIa clinical trial for this therapy was completed in Q4 2013, with
the data analysis thus far concluding that ReJoin^TM cell therapy for KOA
patients is safe and revealing an increase in cartilage thickness as early as
three months after the therapy.

"In the U.S. alone the specific addressable market forecast for KOA stem cell
therapy in 2014 is $83 million (860% growth over 2013) and estimated to grow
to $1.84 billion by 2020. China, with over 57 million people suffering from
KOA, has an even higher demand," commented Bizuo (Tony) Liu, Chief Financial
Officer of Cellular Biomedicine Group, Inc., "Thus we are very pleased to
reach this key milestone bringing us one step closer to improving the quality
of life for countless patients."

About the Clinical Trial

Cellular Biomedicine Group's Phase IIb clinical trial further studies the
efficacy of CBMG's proprietary adipose-derived mesenchymal precursor cell
(haMPC)-based therapy ReJoin^TM for KOA. The multi-center study calls for 48
patients to participate in a randomized, single blind trial.

Knee Osteoarthritis in China

There are approximately 57 million people in China suffering from KOA. As
drug-based methods of management to date are ineffective, the quality of life
for KOA patients is compromised, and many patients with this disease will
degenerate to the point of requiring invasive artificial joint replacement
surgery.

About Cellular Biomedicine Group

Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the
treatment of certain degenerative diseases and cancers. Our developmental stem
cell, progenitor cell, and immune cell projects are the result of research and
development by scientists and doctors fromChinaandthe United States. Our
flagship GMP facility in China, consisting of eight independent cell
production lines, is designed, certified and managed according to U.S.
standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com

Forward-Looking Statements

Statements in this press release relating to plans, strategies, trends,
specific activities or investments, and other statements that are not
descriptions of historical facts may be forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995, Section 27A
of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking information is inherently
subject to risks and uncertainties, and actual results could differ materially
from those currently anticipated due to a number of factors, which include,
but are not limited to, risk factors inherent in doing business.
Forward-looking statements may be identified by terms such as "may," "will,"
"expects," "plans," "intends," "estimates," "potential," or "continue," or
similar terms or the negative of these terms. Although CBMG believes the
expectations reflected in the forward-looking statements are reasonable, they
cannot guarantee that future results, levels of activity, performance or
achievements will be obtained. CBMG does not have any obligation to update
these forward-looking statements other than as required by law.

CONTACT: Sarah Kelly
         Director of Corporate Communications, CBMG
         +1 650 566-5064
         sarah.kelly@cellbiomedgroup.com
        
         Vivian Chen
         Managing Director Investor Relations, Grayling
         +1 646 284-9427
         cbmg@grayling.com
        
         OR
        
         Christopher Chu
         Director Investor Relations, Grayling
         +1 646 284-9426
         cbmg@grayling.com

Cellular Biomedicine Group Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.